Replies to post #26170 on Anavex Life Sciences Corp (AVXL)

[blue finch]

Awesome stuff

[Rwingsguy]

So you're expecting a $500 market cap after Nov 7th (share price $16-$18). That's conservative. But, depending on the data, it could be triple that.

[tootalljones]

retail investors lose confidence due to prior setbacks and frustrations in the stock market.

retail investors also suffer from the adage that "a little learning is a dangerous thing."

"All in good time" is a better expression. And not necessarily every day or week but we are building an R and D powerhouse. The stock market is a perfect organism and will be happy to reflect fair value, over time.

Anavex will be Ain't No Mountain High Enough for the year 2016

[stealthways]

after Nov 7th , next up will be waiting for full P2A part B....which should be out within a few months after..

[powerwalker]

NYC, how did you know on Wednesday that Thursday was going to be "bumpy," (which it was)?

[ClosetInvestor]

What happen to the Biogen announcement to cut employees in order to buy AVXL or another AD candidate? Missed that. I've also missed the post where you provide us with the responses that AVXL's IR gave to your supposed "biotech" knowledge based questions. Will you ever post those?

[ClosetInvestor]

And your $14-16 pps is very conservative. Following the July data we went from the .50 range to $1.67, and then settled. There will be cognition data released on the 7th and the data will no doubt be better than the current SOC. The question is how much data from how many patients over what time period. If the cognition data is good (maybe great) we will go far beyond $16.

[frrol]

It will? You can predict the stock market?! :-)
If the Phase 2A Part A results are good, I suspect the company's market cap will rival and perhaps even pass AXON fully diluted. That would mean mid $20's (we have to include the shares represented by warrants and options). It may hold, it may not. Stocks are volatile, so it will almost certainly "overshoot" and retrace a bit, though at price and when we cannot know; we can't read the minds of thousands of market participants and their trading, investing, tax, and portfolio planning goals. Nor can we predict the timing of any partnership announcement, analyst targets, and bearish articles.
For longs, buy the amount of stock you are comfortable with, keep fingers crossed on Nov 7, and if it's good news continue to hold and ignore the volatility.